NASDAQ · BAX
Healthcare · Medical - Instruments & Supplies
$22.80
Down-$0.22 (-0.96%)
Updated Sep 20, 2026, 10:37 AM
SID Score
5.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
BAX closed at $22.80 after 19 trading sessions, down 13.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $23.05 | $23.155 | $22.7111 | $22.80 | 9.97M |
| Sep 17, 2026 | $23.70 | $23.735 | $22.98 | $23.02 | 6.62M |
| Sep 16, 2026 | $23.76 | $23.865 | $23.18 | $23.53 | 9.45M |
| Sep 15, 2026 | $23.94 | $23.94 | $23.16 | $23.71 | 6.15M |
| Sep 14, 2026 | $24.01 | $24.2179 | $23.605 | $23.86 | 5.74M |
| Sep 11, 2026 | $24.65 | $24.77 | $23.665 | $23.80 | 5.45M |
| Sep 10, 2026 | $24.15 | $24.375 | $23.9238 | $24.18 | 5.75M |
| Sep 9, 2026 | $24.71 | $25.205 | $24.39 | $24.39 | 5.3M |
| Sep 8, 2026 | $25.59 | $25.75 | $24.66 | $24.86 | 5.91M |
| Sep 4, 2026 | $25.33 | $26.115 | $25.26 | $25.83 | 3.42M |
| Sep 3, 2026 | $25.96 | $26.09 | $25.17 | $25.57 | 4.7M |
| Sep 2, 2026 | $25.55 | $26.05 | $25.48 | $25.70 | 4.17M |
| Sep 1, 2026 | $26.31 | $26.56 | $25.17 | $25.48 | 5.28M |
| Aug 31, 2026 | $25.91 | $26.35 | $25.86 | $26.00 | 3.99M |
| Aug 28, 2026 | $25.99 | $26.31 | $25.785 | $26.13 | 3.96M |
| Aug 27, 2026 | $26.06 | $26.435 | $25.815 | $25.93 | 4.5M |
| Aug 26, 2026 | $26.49 | $26.755 | $26.125 | $26.50 | 5.19M |
| Aug 25, 2026 | $26.43 | $26.50 | $26.01 | $26.29 | 3.79M |
| Aug 24, 2026 | $26.37 | $26.61 | $26.065 | $26.49 | 4.43M |
The latest Smart Investors Daily articles mentioning BAX.
BAX research
Company profile and research snapshot.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | Stifel | Hold | — |
| Jul 31, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | TD Cowen | Hold | — |
| Jul 28, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Baxter International Inc. (BAX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 12:45 PM EDTCompany ParticipantsAndrew Hider - CEO,...
Benzinga · Sep 8, 2026
Yahoo · Sep 7, 2026
Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.
Yahoo · Sep 7, 2026
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BAX.
